Skip to main content
Premium Trial:

Request an Annual Quote

Baylor Standardizes on Roche NimbleGen Sequence-Capture Tech for Exome Studies

Premium

By Justin Petrone

Baylor College of Medicine's Human Genome Sequencing Center has standardized its target-enrichment human disease research studies on Roche NimbleGen Sequence Capture Exome technology, Roche said this week.

Baylor plans to sequence more than 5,000 exomes in the next two years to identify genetic variants underlying multiple human diseases. The center will use NimbleGen's SeqCap EZ Exome and customized NimbleGen exome designs as its exome-capture technology of choice, according the firm.

NimbleGen first launched its Sequence Capture application at the end of 2008. The technology allows scientists to select targeted regions of the genome for high-throughput sequencing using the firm's capture arrays. Last year, the company launched SeqCap EZ Exome, an in-solution target-enrichment application.

Using the latter method, Baylor plans to investigate more than 15 diseases, including brain, liver, pancreatic, colon, ovarian and bladder cancers, heart disease, diabetes, autism, and other inherited diseases with the ultimate goal of better understanding causative mutations and their impact on these diseases.

The studies are being supported by multiple funds from the National Institutes of Health and other research consortia, Roche said. BCM-HGSC has also optimized its approach for high-throughput exome capture and sequencing with multiple next-generation sequencing platforms, the company said. Baylor has already captured and sequenced over 2,000 samples, with roughly 1,000 of these using exome sequencing, according to the firm.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.